28 results for "Giving"

AALL1131: Chemotherapy in Treating Young Patients with High-Risk B ALL and Ph-like Sensitive Mutations

This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells.

S1619: Atezolizumab, Pemetrexed, Cisplatin, and Surgery +/- RT for Stage I-III Malignant Mesothelioma

This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy in treating patients with stage I-III pleural malignant mesothelioma. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.

Click here to download the Fast Facts

NRG-GI002: Rectal Cancer and the Effects of Veliparib and Combination Chemotherapy

This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving veliparib with combination chemotherapy and radiation therapy may kill more tumor cells and giving it before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Click here to download the Fast Facts

A011502: Node Positive HER2 Negative Breast Cancer and the Effects of Placebo vs. Aspirin as Adjuvant Therapy

This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Click here to download the Fast Facts

AHEP1531: Cisplatin and Combination Chemotherapy for Hepatoblastoma or Liver Cancer After Surgery

This partially randomized Phase II/III trial studies how well Cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as Cisplatin, Doxorubicin, Fluorouracil, Vincristine sulfate, Carboplatin, Etoposide, Irinotecan, Sorafenib, Gemcitabine and Oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells.

RTOG-1112: Hepatocellular Carcinoma and the Effects of Sorafenib vs SBRT + Sorafenib

This randomized phase III trial studies sorafenib tosylate and stereotactic body radiation therapy to see how well they work compared to sorafenib tosylate alone in treating patients with liver cancer. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stereotactic body radiation therapy may be able to send the radiation dose directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with stereotactic body radiation therapy may kill more tumor cells.

Click here to download the Fast Facts

AALL1631: Imatinib Mesylate and Combination Chemotherapy in Newly Diagnosed Philadelphia Chromosome + ALL

This randomized phase III trial studies how well imatinib mesylate and combination chemotherapy work in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving imatinib mesylate and combination chemotherapy may work better in treating patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

AREN1721: Axitinib and Nivolumab in Treating Unresectable or Metastatic TFE/Translocation Renal Cell Carcinoma

This phase II trial studies how well axitinib and nivolumab works in treating participants with TFE/translocation renal cell carcinoma that cannot be removed by surgery or has spread to other places in the body. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab may work better in treating participants with TFE/translocation renal cell carcinoma.

A041701: Daunorubicin and Cytarabine ± Uproleselan in Treating Older Adult Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

This Phase II / III trial studies how well Daunorubicin and Cytarabine with or without Uproleselan works in treating older adult patients with Acute Myeloid Leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as Daunorubicin and Cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may prevent cancer from returning or getting worse. Giving Daunorubicin and Cytarabine with Uproleselan may work better in treating patients with Acute Myeloid Leukemia compared to Daunorubicin and Cytarabine alone.

Click here to download the Fast Facts

A041501: Inotuzumab Ozogamicin & Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B-Cell ALL

This partially randomized phase III trial studies the side effects of Inotuzumab Ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B Acute Lymphoblastic Leukemia. Monoclonal antibodies, such as Inotuzumab Ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Inotuzumab Ozogamicin with chemotherapy may work better in treating young adults with B Acute Lymphoblastic Leukemia.

Click here to download the Fast Facts

A091605: Pembrolizumab +/- Stereotactic Body Radiation Therapy for Advanced Merkel Cell Cancer

This randomized phase II trial studies how well Pembrolizumab with or without stereotactic body radiation therapy works in treating patients with Merkel Cell Cancer that has spread to other places in the body. Monoclonal antibodies, such as Pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends X-Rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving Pembrolizumab with stereotactic body radiation therapy may work better in treating patients with Merkel Cell Cancer.

Click here to download the Fast Facts

EA8143: Renal Cell Carcinoma and the Effects of Perioperative Nivolumab vs. Observation in Patients

This randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone in treating patients with kidney cancer.

Click here to download the Fast Facts

EAA173: Lenalidomide, and Dexamethasone with or without Daratumumab in Treating Patients with High-Risk Smoldering Myeloma

This Phase III trial studies how well Lenalidomide and Dexamethasone works with or without Daratumumab in treating patients with high-risk Smoldering Myeloma. Drugs used in chemotherapy, such as Lenalidomide and Dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as Daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving Lenalidomide and Dexamethasone with Daratumumab may work better in treating patients with Smoldering Myeloma.

Click here to download the Fast Facts

NRG-GI004: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR Metastatic Colorectal Cancer

This randomized phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient DNA mismatch repair colorectal cancer that has spread to other places in the body. Drugs used in chemotherapy, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab and atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.

Click here to download the Fast Facts

RU011501I: Breast Cancer and of Effects Folate Receptor Alpha Peptide Vaccine, Sargramostim, & Cyclophosphamide

This randomized phase II trial studies how well multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide may work better in treating patients with triple negative breast cancer.

Click here to download the Fast Facts

GOG-0279: Cisplatin + Gemcitabine & Radiation Therapy for Squamous Cell Carcinoma of the Vulva

This phase II trial studies how well radiation therapy works when given with gemcitabine hydrochloride and cisplatin work in treating patients with squamous cell cancer of the vulva that has spread from where it started to nearby tissue or lymph nodes. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy together with gemcitabine hydrochloride and cisplatin may kill more tumor cells.

Click here to download the Fast Facts

A041702: Ibrutinib and Obinutuzumab ± Venetoclax in Treating Older Patients with Untreated Chronic Lymphocytic Leukemia

This Phase III trial studies how well Ibrutinib and Obinutuzumab with or without Venetoclax work in treating older patients with untreated Chronic Lymphocytic Leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with Obinutuzumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as Venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ibrutinib and Obinutuzumab with Venetoclax may work better at treating Chronic Lymphocytic Leukemia compared to Ibrutinib and Obinutuzumab.

Click here to download the Fast Facts

S1613: Trastuzumab + Pertuzumab or Cetuximab + Irinotecan for HER2/Neu Amplified Colorectal Cancer

This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and irinotecan hydrochloride in treating patients with colorectal cancer.

Click here to download the Fast Facts

NRG-GY007: Ruxolitinib, Paclitaxel, & Carboplatin for Stage III-IV Epithelial Ovarian Cancer

This phase I/II partially randomized trial studies the side effects and the best dose of Ruxolitinib Phosphate when given together with Paclitaxel and Carboplatin and to see how well they work in treating patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. Ruxolitinib Phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as Paclitaxel and Carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ruxolitinib Phosphate together with Paclitaxel and Carboplatin may be a better treatment for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Click here to download the Fast Facts

NRG-GU002: Prostate Cancer and the Effects of Anti-Androgen Therapy and Radiation Therapy +/- Docetaxel

This randomized phase II / III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving antiandrogen therapy and radiation therapy with or without docetaxel after surgery may kill any remaining tumor cells.

Click here to download the Fast Facts

S1612: Azacitidine +/- Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone for AML or MDS

This randomized phase II/III trial studies how well azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone work in treating older patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as azacitidine, decitabine, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Midostaurin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone may kill more cancer cells.

Click here to download the Fast Facts

NRG-LU005: Chemoradiation with or without Atezolizumab for Limited Stage Small Cell Lung Cancer

This Phase II / III trial studies how well chemotherapy and radiation therapy with or without Atezolizumab works in treating patients with Limited Stage Small Cell Lung Cancer. Drugs used in chemotherapy, such as Etoposide, Cisplatin, and Carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy X-Rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as Atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving chemoradiation with or without Atezolizumab may work better in treating patients with Limited Stage Small Cell Lung Cancer.

Click here to download the Fast Facts

ANBL1821: Irinotecan Hydrochloride, Temozolomide, and Dinutuximab ± Eflornithine for Relapsed or Refractory Neuroblastoma

This Phase II trial studies how well Irinotecan hydrochloride, Temozolomide, and Dinutuximab work with or without Eflornithine in treating patients with Neuroblastoma that has come back or that isn't responding to treatment. Drugs used in chemotherapy, such as Irinotecan hydrochloride and Temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as Dinutuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Eflornithine blocks the production of chemicals called polyamines that are important in the growth of cancer cells. Giving Eflornithine with Irinotecan hydrochloride, Temozolomide, and Dinutuximab, may work better in treating patients with relapsed or refractory Neuroblastoma.

A171601: Palbociclib and Letrozole or Fulvestrant for ER Positive, HER2 Negative Metastatic Breast Cancer

This phase II trial studies the side effects and how well Palbociclib and Letrozole or Fulvestrant works in treating patients aged 70 years and older with estrogen receptor positive, HER2 negative breast cancer that has spread to other places in the body. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as Letrozole or Fulvestrant, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Palbociclib and Letrozole or Fulvestrant may work better in treating patients with breast cancer. The trial will explore factors other than chronologic age that can affect toxicity rates as identified using a cancer-specific geriatric assessment.

Click here to download the Fast Facts

S1800A: Ramucirumab + Pembrolizumab VS SOC for Stage IV or Recurrent Non-Small Cell Lung Cancer

This Phase II Lung-MAP non-Match treatment trial studies how well Ramucirumab and Pembrolizumab work versus standard of care in treating patients with Non-Small Cell Lung Cancer that is Stage IV or has come back. Immunotherapy with monoclonal antibodies, such as Ramucirumab and Pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in standard of care chemotherapy for Non-Small Cell Lung Cancer, such as Docetaxel, Gemcitabine hydrochloride, and Pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving Ramucirumab and Pembrolizumab together may work better in treating patients with Non-Small Lung Cancer compared to standard of care.

Click here to download the Fast Facts

NRG-GY005: Ovarian, Fallopian Tube, or Peritoneal Cancer and the Effects of Cediranib + / - Olaparib

This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving cediranib maleate and olaparib together may cause more damage to cancer cells when compared to either drug alone or standard chemotherapy.

Click here to download the Fast Facts

ACNS1422: Reduced Craniospinal RT and Chemotherapy for Newly Diagnosed WNT-Driven Medulloblastoma

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

S1608: Follicular Lymphoma and effects of Obinutuzumab +/- PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy

This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy will work better in treating patients with grade I-IIIa follicular lymphoma.

Click here to download the Fast Facts